MAPT and Alzheimer disease: For the comparison with other tau biomarkers, mounting evidence so far points into the direction that CSF p-tau may be more sensitive in detecting tau pathology in the earliest clinical phases of AD [76, 80, 84, 124], although diagnostic accuracy to discriminate MCI patients showed comparable results [81].